Elisabetta Munzone, Medical oncologist and Breast Cancer specialist at the European Institute of Oncology shared a post on LinkedIn:
“Great to present PRE coop ERA today at ESMO Breast 2026.
A key clinical question: can a potent SERD reduce the need for OFS in premenopausal ER+ early Breast Cancer?
- Giredestrant + OFS – deepest Ki67 suppression.
- Giredestrant alone – missed non-inferiority, but retained clear biologic activity.
- Signal stronger in older premenopausal pts.
My takeaway: OFS remains standard, but SERDs may open the door to more personalized endocrine strategies.”
Other articles about Breast Cancer on OncoDaily.
